The vaccine trial processes underway include orientation of the research teams on the trial procedures, and logistics arrangements. Research teams have been deployed to the field to work along with the surveillance teams as approvals are awaited.
As of 30 January, there was one confirmed case and 45 contacts who are being followed up.
WHO is working with the Ministry of Health of Uganda and its designated Ugandan Principal Investigators and their teams from Makerere University Lung Institute and the Ugandan Virus Research Institute, as well as worldwide filovirus and trial experts and regulators, to initiate the trials.
The aim of the vaccine trial is to evaluate a potentially efficacious candidate vaccine, and if efficacious, to possibly contribute to ending the ongoing outbreak and protect populations at risk in the future. Those eligible to join the trial are those at highest risk of SVD, i.e. close contacts of a person who has been confirmed to have had SVD or who has died from the disease. The study sites will therefore be the locations where contacts of the case or cases reside. Study teams will be mobile and able to rapidly move to these areas to do their work using the ring vaccination approach.
The development of the protocols and research priorities has been done via the MARVAC Consortium and the Collaborative Open Research Consortium (CORC) for the Filoviridae Family, and numerous developers facilitated the availability of the candidate vaccine and treatments: IAVI provided their candidate Sudan vaccine, Gilead provided remdesivir, an antiviral.
While outbreaks of SVD are controllable without vaccines, control can be achieved more quickly using safe and effective vaccines. In the meantime, a comprehensive outbreak response is underway in Uganda to rapidly halt transmission, identify contacts and carry out epidemiological investigations, while enhancing community awareness.
Sudan virus disease is a severe, often fatal illness affecting humans and other primates that is due to Orthoebolavirus sudanense (Sudan virus), a viral species belonging to the same genus of the virus causing Ebola virus disease. Case fatality rates of Sudan virus disease have varied from 41% to 100% in past outbreaks. There are no approved treatments or vaccines for Sudan virus, but early initiation of supportive treatment has been shown to significantly reduce deaths from Sudan virus disease.
Read More Details
Finally We wish PressBee provided you with enough information of ( WHO and partners enable access to candidate vaccine and treatments for outbreak of Sudan Ebola virus disease in Uganda )
Also on site :